Skip to main content

Advertisement

SpringerLink
Log in

PROSTATE CANCER

Genomic diversity in low-risk disease: present and future

  • News & Views
  • Published:

From Nature Reviews Urology

View current issue Sign up to alerts

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

New data have confirmed the genomic diversity of low-risk prostate cancer. Improved understanding of the heterogeneity of this disease has implications for disease management and has the potential to change treatment for patients in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Identification of the diverse genomic landscape of low-risk prostate cancer.

References

  1. Cooperberg, M. R. et al. The diverse genomic landscape of clinically low-risk prostate cancer. Eur. Urol. https://doi.org/10.1016/j.eururo.2018.05.014 (2018).

    Article  PubMed  Google Scholar 

  2. Fraser, M. et al. Genomic hallmarks of localized, non-indolent prostate cancer. Nature 541, 359–364 (2017).

    Article  CAS  Google Scholar 

  3. Klein, E. A. et al. Molecular analysis of low grade prostate cancer using a genomic classifier of metastatic potential. J. Urol. 197, 122–128 (2017).

    Article  CAS  Google Scholar 

  4. Spratt, D. E. et al. Development and validation of a novel integrated clinical-genomic risk group classification for localized prostate cancer. J. Clin. Oncol. 36, 581–590 (2018).

    Article  Google Scholar 

  5. Hamdy, F. C. et al. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N. Engl. J. Med. 375, 1415–1424 (2016).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Mayo Clinic, Rochester, MN, USA

    Vidit Sharma & R. Jeffrey Karnes

Authors
  1. Vidit Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Jeffrey Karnes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Jeffrey Karnes.

Ethics declarations

Competing interests

R.J.K. declares research funding from GenomeDx and royalties related to Decipher. V.S. declares no competing interests.

Additional information

Related links

Decipher Genomic Resource Information Database: http://www.deciphergrid.com

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sharma, V., Karnes, R.J. Genomic diversity in low-risk disease: present and future. Nat Rev Urol 15, 594–596 (2018). https://doi.org/10.1038/s41585-018-0073-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41585-018-0073-2

  • Springer Nature Limited

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Search

Navigation